Screener
Organon OGN CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other | 8 | 40 |
| Net Cash Flows Provided by Operating Activities | 225 | 75 |
| Cash Flows from Investing Activities | ||
| Capital expenditures | (37) | (32) |
| Acquired in-process research and development and milestones | (10) | (10) |
| Proceeds from sale of Jada | 433 | — |
| Dermavant acquisition, net of cash acquired | — | (75) |
| Purchase of product rights and asset acquisition | — | (55) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's capex?
- Organon (OGN) reported capex of $37M in Q1 2026.
- How has Organon's capex changed year-over-year?
- Organon's capex increased by 15.6% year-over-year, from $32M to $37M.
- What is the long-term trend for Organon's capex?
- Over 4 years (2021 to 2025), Organon's capex has grown at a -4.2% compound annual growth rate (CAGR), from $192M to $162M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Organon's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude